Skip to main content
. 2021 Mar 15;29(1):113–127. doi: 10.38212/2224-6614.3230

Fig. 3.

Fig. 3

PRODH overexpression sensitized TNBC tumor cells to clinical therapeutic drugs. (a) Wild-type HS578T, PRODH-overexpressing, and vector control cells were treated with clinical therapeutic agents, including (a) lipodox (0–1 μg/mL) and (b) palbociclib (0.05–5 μM) for 4 days. The cell growth number was calculated, and the results revealed that inhibition of cell viability was only observed in the PRODH-overexpressing cells.